NeXeption is the partner of choice for accelerating therapies through clinical and regulatory milestones

NeXeption builds innovative companies by bringing together pharmaceutical product opportunities, management expertise and the necessary funding to rapidly advance therapies through clinical and regulatory milestones.


Our experienced team of pharmaceutical and biotechnology executives has a proven track record of identifying, developing, registering and commercializing new products. The following companies formed by members of the management team have been successfully partnered, generating high returns for investors.



How we're different

Our unique business model creates, funds and manages independent operating companies focused solely on maximizing the value of each potential opportunity. We target programs that address unmet medical needs and have a high technical probability of success.


we offer an alternative pipeline development path for non-progressing assets or science.


we provide the appropriate resources and access to capital to advance assets from concept through commercialization.


we have a consistent track record of high returns.

NeXeption is actively seeking additional development-ready assets across a broad range of therapeutic areas.

Based in Philadelphia

One of the nation's largest R&D hubs and

growing center of healthcare innovation

NeXeption is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

April 10, 2020

FDA Grants Orphan Drug Designation to NexEos Bio’s Investigational Radioimaging Agent as a Diagnostic for the Management of Eosinophilic Esophagitis

January 8, 2020

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline

March 28, 2019

Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)

October 16, 2018

Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent

August 14, 2018

FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans

Please reload